We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -2.13% | 23.00 | 22.00 | 24.00 | 24.00 | 24.00 | 24.00 | 86,635 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.89 | 17.79M |
From Apr 2021 to Apr 2024
TIDMONC
RNS Number : 7544D
Oncimmune Holdings PLC
01 July 2021
1 July 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Total Voting Rights
In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.
Pursuant to the Company's existing block admission, and following the exercise of options over 6,482 ordinary shares in aggregate during May and June 2021 by current and former employees, as at 30 June 2021, the Company's issued share capital was 69,121,949 ordinary shares of GBP0.01 each with voting rights. The Company does not hold any shares in treasury.
The above figure of 69,121,949 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information:
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Claes Sp å ng
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVREAAKEDEFFEAA
(END) Dow Jones Newswires
July 01, 2021 02:00 ET (06:00 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
